Lv42
680 积分 2022-11-07 加入
From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
21分钟前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
3小时前
已完结
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
3小时前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
12小时前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
1天前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
3天前
已完结
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials
6天前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
7天前
已关闭
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
22天前
已完结
皖公网安备34019202002308
